Calling all sports tech startups ready to scale. Photo via Getty Images

Familiar names within Houston innovation have teamed up to launch a program for sports tech startups ready to scale.

Pokatok Labs announced five companies that make up its inaugural cohort. Pokatok is founded by Lawson Gow, founder of The Cannon; Chris Buckner, founder of Mainline; and Alex Gras, former chief commercial officer of The Cannon. (Note: Lawson Gow is the son of David Gow, the CEO of InnovationMap's parent company, Gow Media.)

The new program is targeting growing seed and series A startups across the scope of sports technology — health tech, gaming, fan experience, and more. The nine-week program is free to its cohort member and will run twice a year. Participating companies receive access to a network of organizations, advisors, investors, and subject matter experts within sports tech.

“Houston has a huge potential to emerge as a global leader in sports innovation, and the launch of this program is an important step in that direction,” says Gow, who serves as Pokatok's CEO.

The program will be housed in The Cannon Sports in 53West, which opened last year. Kate Evinger, who previously oversaw gBETA Houston's early stage accelerator, will lead Pokatok Labs as director.

“Each of the five companies are true disruptors within the global sports community. It is a privilege and an honor to be working alongside them, and we look forward to the great things to come from each '' Evinger says.

The first cohort of startups includes:

  • Detroit, Michigan-based Miro AI builds cutting-edge computer vision that analyzes images and videos to unlock athlete data. The technology has analyzed over 50 million athletes.
  • Monarc, headquartered in Dallas, has created a robotic quarterback called the Seeker. Several universities — like West Virginia University, Louisiana State University, and Washington University — have already tapped into the technology, as well as NFL professionals, including George Kittle, James White and Adrian Amos.
  • RE Cooling Tech, based in Lafayette, Louisiana, has a technology that cools and increases the performance of athletes before, during, and after physical exertion. The technology was validated in a study with The Korey Stringer Institute at the University of Connecticut showing efficacy in cooling and increased athletic performance.
  • Founded at MIT, Perch uses computer vision and machine learning to seamlessly track exercise, provide real time feedback, facilitate new types of competitions, and store the data for later analysis and progress tracking. The company has sold to more than 10 NFL teams, supporting two national championship college football teams, as well as a growing number of professional sports teams, colleges, military, high schools, performance facilities, and even individual home gyms.
  • Pennsylvania-based Reflexion is a portable neuro training service that gives athletes an edge with interactive lightboard based drills. Reflexion has raised over $4 million in venture funding to date, is used by thousands of athletes in homes and training centers, and is trusted by the likes of Under Armour, the Canadian National Soccer Team, and the Denver Nuggets.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”

Houston startup raises $6M to scale home-based healthcare platform

fresh funding

As healthcare systems race to expand care beyond hospitals and into the home, investors are placing bigger bets on the infrastructure needed to make that shift possible.

This month, Rosarium Health announced it has raised $6 million in seed funding led by Kalos Ventures, with participation from ResilienceVC, Rock Health Capital, Symphonic Capital, Black Tech Nations Ventures and others.

The investment will help the Houston-based startup continue to build its platform, which features a national network of 800-plus clinicians and 3,000-plus contractors to coordinate home accessibility upgrades and modifications for seniors and people living with disabilities.

For founder and CEO Cameron Carter, the company’s mission grew out of firsthand caregiving experiences.

“From my own personal caregiving experiences, I realized that the benefits exist on paper, but not in reality,” Carter said in a news release. “Families are being left to figure out the paperwork and installations all on their own, which shouldn’t be how this works.”

While Medicare Advantage and Medicaid plans have expanded coverage for home-based services and accessibility modifications, the logistics behind delivering those services often remain fragmented.

Rosarium’s platform coordinates the entire process, from clinical assessments and referrals to contractor management, documentation, reimbursement and installation.

“A clinician can document that a home isn’t safe and a plan can approve a benefit, but there’s no one that’s responsible for making sure the work actually gets done,” Carter says. “We built the missing piece.”

The company was founded in 2021 as Rose Health and was a 2023 participant in the Texas Medical Center’s Accelerator for HealthTech program. It has scaled quickly, building a network of more than 800 clinicians and 3,000 contractors across 34 states.

Rosarium is currently in-network for 1.2 million Medicare and Medicaid lives, with projected coverage expected to reach nearly 4 million by the end of the year, according to the release.

“We’re excited to back Cameron because he and the team at Rosarium are building the infrastructure healthcare needs right now to make the home a safe and comfortable place of care,” Kate Ballinger, investor at Kalos Ventures, added in the release.

As part of the recent investment, Ballinger will join Rosarium’s board of directors.

With eyes on the future, Rosarium plans to grow its partnerships with Medicaid and Medicare Advantage plans, including CalViva and Community Health Plan of Imperial Valley, strengthening its presence in California while expanding access to underserved communities.

Additionally, Carter predicts that home-based healthcare will be part of a broader transformation happening across the industry.

“There’s a growing recognition that health outcomes are shaped by what happens in the home,” he said in the release. “The future of healthcare isn’t just treating people after something goes wrong. It’s creating environments that help prevent those problems in the first place.”